Kingdon Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Kingdon Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-575,000	Closed	-$19.3M	–	89
2026 Q1	$19.3M	Buy	575,000 +175,100	+44%	+$6.87M	2.11%	8
2025 Q4	$18.5M	Buy	399,900 +98,900	+33%	+$5.42M	2.2%	10
2025 Q3	$20.3M	Buy	+301,000	New	+$22.3M	2.53%	6

Kingdon Capital Management's SLNO Position: Q2 2026 in Review

Kingdon Capital Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 575,000 shares — an estimated $19.3M sold.

Kingdon Capital Management first reported a position in SLNO in Q3 2025 and held it in 3 quarters. The position peaked at $20.3M in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Kingdon Capital Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Kingdon Capital Management sold 575,000 Soleno Therapeutics shares in Q2 2026, an estimated $19.3M.
Kingdon Capital Management first reported a position in Soleno Therapeutics in Q3 2025 and held it in 3 quarters.
Kingdon Capital Management's Soleno Therapeutics position peaked at $20.3M in Q3 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Kingdon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.